^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HMBD-501

    i
    Other names: HMBD-501, ENV-501
    Company:
    Endeavor BioMed, Hummingbird Biosci
    Drug class:
    Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate
    Related drugs:
    1year
    HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models (AACR 2023)
    Patritumab-Deruxtecan (U3-1402), a HER3-targeting ADC, showed clinical response in a subset of EGFR mutant and TKI resistant lung cancers in a Phase 1 study, albeit with toxicities including severe interstitial lung disease (ILD) and high grade cytopenias. In conclusion, HMBD-501 represents a next generation HER3 targeting ADC that has a potentially best-in-class efficacy and tolerability profile. Our findings strongly support the development of HMBD-501 as a promising candidate in the treatment of HER3 expressing solid tumors.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • NRG1 (Neuregulin 1) • FCGR2A (Fc fragment of IgG receptor IIa)
    |
    EGFR mutation • ERBB3 expression • ERBB3 overexpression
    |
    patritumab deruxtecan (U3-1402) • HMBD-501